EDISON, N.J.—Carotech will showcase its latest liver and brain health studies at Ingredient Marketplace 2014. The results come from the clinical studies on Tocomin SupraBio®, a bio-enhanced full spectrum palm tocotrienol complex. Two recent human clinical studies respectively provided strong and significant evidence that oral supplementation with Tocomin SupraBio® improves fatty liver in nonalcoholic fatty liver disease (NAFLD) and slows the progression of white matter lesions (WMLs) in human brain.
“Another exciting health benefit of Tocomin SupraBio® is its neuroprotection effects," said regional product manager, Bryan See. He said researchers at Ohio State University Medical Center have been studying the neuroprotective property of palm tocotrienol complex. “A recent ground-breaking human clinical study (published in the American Heart Association’s journal, STROKE), conducted at the University Science of Malaysia conclusively showed that supplementation with Tocomin SupraBio® attenuates the progression of brain white matter lesions, which is often linked to vascular events of the brain and is an indication of fragile brain vascular network. WMLs are also linked to increased stroke risk, and development of other neurodegenerative disease."